ABL DiagnosticsXPAR:ABLD +0.76%51 Days Payable is 1,041.55 as of Dec. 2025, which is 45% below its 10-year median of 1,895.96. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 605 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 97.36% on this metric.
The historical rank and industry rank for ABL Diagnostics's Days Payable or its related term are showing as below:
XPAR:ABLD'
s Days Payable Range Over the Past 10 Years
Min: 1712.69 Med: 1895.96 Max: 2129.72
Current: 1833.93
During the past 13 years, ABL Diagnostics's highest Days Payable was 2129.72. The lowest was 1712.69. And the median was 1895.96.
XPAR:ABLD's Days Payable is ranked better than 97.36% of 605
companies
in the Healthcare Providers & Services industry
Industry Median: 57.51
vs XPAR:ABLD: 1833.93
ABL Diagnostics's Days Payable
increased
from Dec. 2024 (0.00) to Dec. 2025 (1,041.55).
It may suggest that ABL Diagnosticsdelayed paying its suppliers.
ABL Diagnostics Days Payable Related Terms
ABL Diagnostics Days Payable Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, TEM: Days Payable Comparison
For the Health Information Services subindustry, ABL Diagnostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Days Payable distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ABL Diagnostics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (XPAR:ABLD) has a Days Payable of 1,041.55 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ABL Diagnostics and its competitors. This is 45% below median its historical median of 1,895.96. Over the past decade, ABL Diagnostics' Days Payable has ranged from 1,712.69 to 2,129.72. According to the industry distribution chart, ABL Diagnostics ranks #16 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 2.6%.
Is ABL Diagnostics' Days Payable too high?
ABL Diagnostics' current Days Payable of 1,041.55 is 45% below median its 10-year median of 1,895.96. Over the past 10 years, this metric has ranged from a low of 1,712.69 to a high of 2,129.72. The Healthcare Providers & Services industry median Days Payable is 57.51. ABL Diagnostics' value of 1,041.55 is 1711.1% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #16 out of 605 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Days Payable compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #16 out of 605 companies for Days Payable. This places ABL Diagnostics in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 57.51. ABL Diagnostics' value of 1,041.55 is 1711.1% above this benchmark. Historically, ABL Diagnostics' own Days Payable has ranged from 1,712.69 to 2,129.72 over the past decade. While the company's 10-year median is 1,895.96 vs. the industry median of 57.51, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 57.51, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current Days Payable of 1,041.55 is 1711.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 57.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current Days Payable is 1,041.55, which is 45% below median its own 10-year median of 1,895.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current Days Payable is 1,041.55, which is 45% below median its 10-year median of 1,895.96 and 1711.1% above the Healthcare Providers & Services industry median of 57.51. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Days Payable is 1,041.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Days Payable: 1,041.55 (45% below median its 10-year median of 1,895.96)
GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
Industry Position: 1711.1% above the Healthcare Providers & Services median (#16 of 605)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score
Get the complete analysis for XPAR:ABLD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
